Antiphospholipid autoantibody detection is important in all patients with systemic autoimmune diseases

Marziale, Adrien; Bettacchioli, Éléonore; Picart, Gael; Nafai, Salma; Galinat, Hubert; Meroni, Pier Luigi; Frostegård, Johan; Alarcón‐Riquelme, Marta E.; Renaudineau, Yves

doi:10.1016/j.jaut.2020.102524

Cited by 16 publications

(7 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exposure of cardiolipin on the outer face of mitochondria also contributes to NLRP3 inflammasome activation, as previously discussed ( 161 , 162 , 201 ). Anti-cardiolipin antibodies can be detected in samples from RA patients, although these are more frequently associated with primary antiphospholipid syndrome or SLE ( 202 ), and this autoimmunity does not constitute true DAMP activity.…”

Section: Mitochondrial Dampsmentioning

confidence: 99%

Mitochondria as Key Players in the Pathogenesis and Treatment of Rheumatoid Arthritis

et al. 2021

View full text Add to dashboard Cite

Mitochondria are major energy-producing organelles that have central roles in cellular metabolism. They also act as important signalling hubs, and their dynamic regulation in response to stress signals helps to dictate the stress response of the cell. Rheumatoid arthritis is an inflammatory and autoimmune disease with high prevalence and complex aetiology. Mitochondrial activity affects differentiation, activation and survival of immune and non-immune cells that contribute to the pathogenesis of this disease. This review outlines what is known about the role of mitochondria in rheumatoid arthritis pathogenesis, and how current and future therapeutic strategies can function through modulation of mitochondrial activity. We also highlight areas of this topic that warrant further study. As producers of energy and of metabolites such as succinate and citrate, mitochondria help to shape the inflammatory phenotype of leukocytes during disease. Mitochondrial components can directly stimulate immune receptors by acting as damage-associated molecular patterns, which could represent an initiating factor for the development of sterile inflammation. Mitochondria are also an important source of intracellular reactive oxygen species, and facilitate the activation of the NLRP3 inflammasome, which produces cytokines linked to disease symptoms in rheumatoid arthritis. The fact that mitochondria contain their own genetic material renders them susceptible to mutation, which can propagate their dysfunction and immunostimulatory potential. Several drugs currently used for the treatment of rheumatoid arthritis regulate mitochondrial function either directly or indirectly. These actions contribute to their immunomodulatory functions, but can also lead to adverse effects. Metabolic and mitochondrial pathways are attractive targets for future anti-rheumatic drugs, however many questions still remain about the precise role of mitochondrial activity in different cell types in rheumatoid arthritis.

show abstract

Section: Mitochondrial Dampsmentioning

confidence: 99%

Mitochondria as Key Players in the Pathogenesis and Treatment of Rheumatoid Arthritis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Data regarding disease activity using a cut-off point ≥5 from the SLEDAI-2K score [ 11 ], clinical presentation, current treatment, number and time of covid-19 vaccine injections or infectious episodes were retrospectively collected from medical records. Laboratory data included lymphocyte count, albumin and gamma-globulin levels using serum protein electrophoresis, IgG anti-double stranded (ds)DNA and anti-chromatin Abs (Bioplex, Biorad, Hercules, CA), IgG anti-extractable nuclear Abs, antiphospholipid Abs such as anticardiolipin (aCL) and anti-beta2 glycoprotein I (aβ2-GPI) Abs, and the complement fractions C3, C4 and CH50 (The Binding Site, Birmingham, UK) [ [12] , [13] , [14] , [15] ].…”

Section: Methodsmentioning

confidence: 99%

Glucocorticoids selectively affect the memory T cell response to SARS-Cov2 spike in vaccinated and post-infected patients with systemic lupus erythematosus

Renaudineau¹,

Bost²,

Abravanel³

et al. 2023

Journal of Translational Autoimmunity

Self Cite

View full text Add to dashboard Cite

“…A persistent detection of anti-phospholipids (>12 weeks) is retrieved in 20-40% of SLE patients, which increases the risk of arterial/venous thrombosis and/or pregnancy morbidity [89]. Among LN patients, 5-15% of them present glomerular microvascular damage at biopsy that defines anti-phospholipid nephropathy (APSN) [90], and this distinct histological feature and independent risk factor for ESKD development results from the presence of an acute and/or chronic thrombotic microangiopathy (TMA) together with serum anti-phospholipid Ab detection [91,92].…”

Section: Anti-phospholipid Antibodiesmentioning

confidence: 99%

Lupus Nephritis Risk Factors and Biomarkers: An Update

Renaudineau,

Brooks,

Belliere

2023

IJMS

Self Cite

View full text Add to dashboard Cite

Lupus nephritis (LN) represents the most severe organ manifestation of systemic lupus erythematosus (SLE) in terms of morbidity and mortality. To reduce these risks, tremendous efforts have been made in the last decade to characterize the different steps of the disease and to develop biomarkers in order to better (i) unravel the pre-SLE stage (e.g., anti-nuclear antibodies and interferon signature); (ii) more timely initiation of therapy by improving early and accurate LN diagnosis (e.g., pathologic classification was revised); (iii) monitor disease activity and therapeutic response (e.g., recommendation to re-biopsy, new urinary biomarkers); (iv) prevent disease flares (e.g., serologic and urinary biomarkers); (v) mitigate the deterioration in the renal function; and (vi) reduce side effects with new therapeutic guidelines and novel therapies. However, progress is poor in terms of improvement with early death attributed to active SLE or infections, while later deaths are related to the chronicity of the disease and the use of toxic therapies. Consequently, an individualized treat-to-target strategy is mandatory, and for that, there is an unmet need to develop a set of accurate biomarkers to be used as the standard of care and adapted to each stage of the disease.

show abstract

Antiphospholipid autoantibody detection is important in all patients with systemic autoimmune diseases

Cited by 16 publications

References 41 publications

Mitochondria as Key Players in the Pathogenesis and Treatment of Rheumatoid Arthritis

Mitochondria as Key Players in the Pathogenesis and Treatment of Rheumatoid Arthritis

Glucocorticoids selectively affect the memory T cell response to SARS-Cov2 spike in vaccinated and post-infected patients with systemic lupus erythematosus

Lupus Nephritis Risk Factors and Biomarkers: An Update

Contact Info

Product

Resources

About